Verde Science, Inc.

VRCI

US92337L2034

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 18:10:42 22/03/2024 GMT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2021	Verde Science : Two more UK energy suppliers stop trading on gas price hit	RE
2018	Verde Science, Inc. Announces Executive Changes	CI

Verde Science, Inc. Appoints Bradley J. Dixon, J.D. to the Board of Directors

June 18, 2014 at 07:38 pm

Verde Science, Inc. announced the appointment of Bradley J. Dixon, J.D. to the Board of Directors. Mr. Dixon is a trial attorney and partner in the Boise, Idaho office of Stoel Rives, LLP.

Latest news about Verde Science, Inc.

Verde Science : Two more UK energy suppliers stop trading on gas price hit	22/09/21	RE
Verde Science, Inc. Announces Executive Changes	28/06/18	CI
Verde Science, Inc. Announces Management Changes	30/01/18	CI
Verde Science, Inc. Announces Management Changes	06/12/17	CI
Verde Science, Inc. Announces Plan to Study Cannabis Preparation for Treatment of Huntingdon's Disease	09/10/15	CI
Verde Science, Inc. Announces Board Changes	18/09/15	CI
Verde Science, Inc. Appoints Harpreet Sangha as Interim Chief Financial Officer	31/07/15	CI
Verde Science Appoints Bradley J. Dixon and John Percival to Board of Directors	27/05/15	CI
Verde Science, Inc. Appoints David Alexander as Chief Financial Officer	27/05/15	CI
Verde Science, Inc. Auditor Raises 'Going Concern' Doubt	19/04/15	CI
Verde Science, Inc. will Change its Ticker to VRCI from VRCI.D	11/02/15	CI
Verde Science, Inc. will Change its Ticker to VRCI.D from VRCI	14/01/15	CI
Rango Energy Inc. cancelled the acquisition of INNEX Energy, L.L.C.	02/12/14	CI
ID Global Corporation Signs a Binding Memorandum of Understanding with Verde Science, Inc	01/10/14	CI
Verde Science, Inc. Announces Research and Development Alliance with an Indian Pharmaceutical Company	23/09/14	CI
Hangtown Energy Inc. cancelled the acquisition of Rango Energy Inc. in a reverse merger transaction.	15/08/14	CI
Verde Science, Inc. announced that it has received $0.8 million in funding.	27/06/14	CI
Verde Science, Inc. Appoints Bradley J. Dixon, J.D. to the Board of Directors	18/06/14	CI
Verde Science, Inc. Appoints Ken Berscht to the Position of CEO	16/06/14	CI
Verde Science, Inc. Signs First Long Term Advisory Services Contract with Los Angeles County Medical Marijuana Dispensary	02/06/14	CI
Verde Science, Inc. announced that it expects to receive $0.30 million in funding.	28/05/14	CI
Verde Science, Inc. Announces the Appointment of Paul Pelosi to its Advisory Board	22/05/14	CI
Rango Energy Inc. cancelled the acquisition of 75% stake in 6,000 acres located in the Ft. Worth Basin from Proco Operating Co. Inc.	15/05/14	CI
Verde Science, Inc. Appoints Luis Bobadilla III as its Board Directors	14/05/14	CI
Rango Energy Inc. has Changed its Name to Verde Science, Inc	07/05/14	CI

Verde Science, Inc. is a pharmaceutical research and development company. The Company is engaged in medical science consulting business. The Company is focused on the discovery of drugs and treatment modalities, as well as diagnostic devices and pharmaceutical delivery systems for the treatment of diseases and medical issues. The Company is focused on developing medicinal formulations from cannabinoids and tetrahydrocannabinol (THC) compounds for the treatment of various issues, such as migraines, glaucoma, loss of appetite from cancer therapies, and other medical issues. The Company is focused on launching its THC Pharmaceutical Development Program by executing a research program, which involves developing formulations preparing protocols for clinical trials.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERDE SCIENCE, INC.	-.--%	23
VERTEX PHARMACEUTICALS INCORPORATED	+5.33%	111B
REGENERON PHARMACEUTICALS, INC.	+12.11%	105B
BIONTECH SE	-12.56%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-10.86%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+5.10%	13.7B
SAREPTA THERAPEUTICS, INC.	+37.57%	12.45B

Bio Therapeutic Drugs